| Date |
Press Releases |
Link to PDF File |
| Sept. 16, 2008 |
NeurAxon Appoints Thomas Lategan, PhD as Vice President of Regulatory Affairs |
|
| Sept. 5, 2008 |
NeurAxon’s NXN-188 Demonstrates Pain Relief in Migraine with Aura |
|
| June 17, 2008 |
NeurAxon, Inc. to Present at BIO International Convention June 18, 2008 |
|
| Mar 25, 2008 |
NeurAxon, Inc. to Present at the BioCentury Future Leaders
Conference March 27, 2008
|
|
| Mar. 11, 2008 |
NeurAxon Announces the Appointment of David Brand
to Its Board of Directors |
|
| Feb. 7, 2008 |
NeurAxon, Inc. to Present at 10th Annual BIO CEO & Investor Conference |
|
| Jan. 4, 2008 |
NeurAxon, Inc. to Present at 26th Annual JPMorgan Healthcare Conference January 10, 2008 |
|
| Aug. 20, 2007 |
NeurAxon Announces $32 Million Series B Financing |
|
| Aug. 14, 2007 |
NeurAxon Announces Positive Phase 1 Trial Data on NXN-188 for Migraine |
|
| Aug. 7, 2007 |
NeurAxon Appoints Robert Medve, M.D., as Chief Medical and Regulatory Officer |
|
| July 31, 2007 |
NeurAxon Appoints Lawrence E. Bloch, M.D., J.D., as Chief Executive Officer |
|
|
